ES2378090T3 - Clústeres de genes biosintéticos lantibióticos a partir de A. garbadinensis y A. liguriae - Google Patents

Clústeres de genes biosintéticos lantibióticos a partir de A. garbadinensis y A. liguriae Download PDF

Info

Publication number
ES2378090T3
ES2378090T3 ES07704921T ES07704921T ES2378090T3 ES 2378090 T3 ES2378090 T3 ES 2378090T3 ES 07704921 T ES07704921 T ES 07704921T ES 07704921 T ES07704921 T ES 07704921T ES 2378090 T3 ES2378090 T3 ES 2378090T3
Authority
ES
Spain
Prior art keywords
actagardin
compound
seq
polypeptide
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07704921T
Other languages
English (en)
Spanish (es)
Inventor
Steven Boakes
Jesus Cortes Bargallo
Michael John Dawson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novacta Biosystems Ltd
Original Assignee
Novacta Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacta Biosystems Ltd filed Critical Novacta Biosystems Ltd
Application granted granted Critical
Publication of ES2378090T3 publication Critical patent/ES2378090T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/365—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinoplanes (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/045—Actinoplanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES07704921T 2006-01-17 2007-01-17 Clústeres de genes biosintéticos lantibióticos a partir de A. garbadinensis y A. liguriae Active ES2378090T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0600928.6A GB0600928D0 (en) 2006-01-17 2006-01-17 Improvements relating to lantibiotics
GB0600928 2006-01-17
PCT/GB2007/000138 WO2007083112A2 (en) 2006-01-17 2007-01-17 Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae

Publications (1)

Publication Number Publication Date
ES2378090T3 true ES2378090T3 (es) 2012-04-04

Family

ID=35998187

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07704921T Active ES2378090T3 (es) 2006-01-17 2007-01-17 Clústeres de genes biosintéticos lantibióticos a partir de A. garbadinensis y A. liguriae

Country Status (20)

Country Link
US (3) US7989416B2 (US07794700-20100914-C00152.png)
EP (2) EP2189472A1 (US07794700-20100914-C00152.png)
JP (1) JP5219837B2 (US07794700-20100914-C00152.png)
KR (1) KR101573536B1 (US07794700-20100914-C00152.png)
CN (1) CN101389641B (US07794700-20100914-C00152.png)
AT (1) ATE534659T1 (US07794700-20100914-C00152.png)
AU (1) AU2007206769B2 (US07794700-20100914-C00152.png)
BR (1) BRPI0706525A2 (US07794700-20100914-C00152.png)
CA (1) CA2637315A1 (US07794700-20100914-C00152.png)
CY (1) CY1112559T1 (US07794700-20100914-C00152.png)
DK (1) DK1979375T3 (US07794700-20100914-C00152.png)
ES (1) ES2378090T3 (US07794700-20100914-C00152.png)
GB (1) GB0600928D0 (US07794700-20100914-C00152.png)
IL (1) IL192446A0 (US07794700-20100914-C00152.png)
MX (1) MX2008009047A (US07794700-20100914-C00152.png)
NZ (1) NZ569486A (US07794700-20100914-C00152.png)
PL (1) PL1979375T3 (US07794700-20100914-C00152.png)
PT (1) PT1979375E (US07794700-20100914-C00152.png)
SI (1) SI1979375T1 (US07794700-20100914-C00152.png)
WO (1) WO2007083112A2 (US07794700-20100914-C00152.png)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714029D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
AU2010205472B2 (en) * 2009-01-14 2013-03-14 Novacta Biosystems Limited Deoxyactagardine derivatives
SG173504A1 (en) * 2009-02-04 2011-09-29 Novacta Biosystems Ltd Actagardine derivatives
CA2789164A1 (en) 2010-02-02 2011-08-11 Novacta Biosystems Limited Lantibiotic salts
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
EP2627320A1 (en) 2010-07-14 2013-08-21 Novacta Biosystems Limited Formulation comprising a type b lantibiotic
GB201013513D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
WO2014085637A1 (en) * 2012-11-30 2014-06-05 Sentinella Pharmaceuticals, Inc. New lantibiotic derivatives and a process for their preparation
CN103483433B (zh) * 2013-09-10 2015-05-27 中国科学院微生物研究所 一种新型高效的羊毛硫细菌素cerecidin及其应用
CN106188253B (zh) * 2016-08-26 2020-08-18 上海交通大学 抗菌肽Lexapeptide及其制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (US07794700-20100914-C00152.png) 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
ATE255165T1 (de) 1994-09-12 2003-12-15 Aventis Pharma Gmbh Rekombinantes mersacidin und verfahren zu seiner herstellung
JP4236699B2 (ja) 1995-06-23 2009-03-11 アンビィー インコーポレイテッド 抗生物質抵抗性グラム陽性細菌の制御および感染治療の方法
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5985823A (en) 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
DE19745583A1 (de) * 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
PL202623B1 (pl) 2000-06-28 2009-07-31 Smithkline Beecham Plc Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna
GB0110432D0 (en) * 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
CA2501855A1 (en) 2002-10-10 2004-04-22 Molichem Medicines, Inc. Nucleic acids encoding duramycin
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
CA2529124C (en) 2003-07-18 2011-02-08 Vicuron Pharmaceuticals Inc. Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof
AU2005215017A1 (en) * 2004-02-17 2005-09-01 Cancervax Corporation Method and composition for angiogenesis inhibition
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
WO2007036706A1 (en) 2005-09-27 2007-04-05 Novacta Biosystems Limited Variants of the lantibiotic mersacidin and their use
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
ES2895666T3 (es) 2006-10-27 2022-02-22 Capsugel Belgium Nv Cápsulas duras de hidroxipropilmetilcelulosa y proceso de fabricación
US20110150917A1 (en) 2007-06-12 2011-06-23 The University Of British Columbia Small Cationic Antimicrobial Peptides
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
BRPI0822946A2 (pt) 2008-11-24 2015-06-23 Sentinella Pharmaceuticals Inc Sentinella Derivado de carboxiamida, processo para preparação de derivado de carboxiamida, composição farmacêutica e uso do derivado de carboxiamida
AU2010205472B2 (en) 2009-01-14 2013-03-14 Novacta Biosystems Limited Deoxyactagardine derivatives
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
SG173504A1 (en) 2009-02-04 2011-09-29 Novacta Biosystems Ltd Actagardine derivatives
EP2216937A1 (en) 2009-02-10 2010-08-11 Alcatel Lucent Alarm notification between customer premises equipment and a remote management server

Also Published As

Publication number Publication date
AU2007206769A1 (en) 2007-07-26
EP1979375B9 (en) 2012-05-09
KR20080086517A (ko) 2008-09-25
CN101389641A (zh) 2009-03-18
ATE534659T1 (de) 2011-12-15
US20110306091A1 (en) 2011-12-15
WO2007083112A2 (en) 2007-07-26
IL192446A0 (en) 2008-12-29
DK1979375T3 (da) 2012-03-19
MX2008009047A (es) 2008-12-18
JP5219837B2 (ja) 2013-06-26
WO2007083112A3 (en) 2008-05-08
CY1112559T1 (el) 2016-02-10
US8465947B2 (en) 2013-06-18
PT1979375E (pt) 2012-03-06
US20100048459A1 (en) 2010-02-25
KR101573536B1 (ko) 2015-12-11
EP1979375B1 (en) 2011-11-23
CN101389641B (zh) 2013-06-05
GB0600928D0 (en) 2006-02-22
EP2189472A1 (en) 2010-05-26
CA2637315A1 (en) 2007-07-26
USRE45003E1 (en) 2014-07-08
PL1979375T3 (pl) 2012-04-30
BRPI0706525A2 (pt) 2011-03-29
AU2007206769B2 (en) 2013-06-20
SI1979375T1 (sl) 2012-03-30
JP2009523777A (ja) 2009-06-25
US7989416B2 (en) 2011-08-02
NZ569486A (en) 2011-07-29
EP1979375A2 (en) 2008-10-15

Similar Documents

Publication Publication Date Title
ES2378090T3 (es) Clústeres de genes biosintéticos lantibióticos a partir de A. garbadinensis y A. liguriae
Boakes et al. Generation of an actagardine A variant library through saturation mutagenesis
PT97390A (pt) Processo de producao de derivados da eritromicina e de microorganismos geneticamente modificados
US11548916B2 (en) Anti-infective compound
AU2008285655B2 (en) Thiopeptide precursor protein, gene encoding it and uses thereof
JP4913588B2 (ja) ファルネシルベンゾジアゼピノンの製造方法及び薬剤としての使用
CA2446010A1 (en) Production of the lantibiotic cinnamycin with genes isolated from streptomyces cinnamoneus
JP2010535492A (ja) ランチビオティック１０７８９１の生合成のための遺伝子およびタンパク質
FI117674B (fi) Polypeptidit, jotka liittyvät streptogramiinien biosynteesiin, näitä polypeptidejä koodittavat nukleotidisekvenssit, ja niiden käyttö
JP2023012549A (ja) 改変ストレプトマイセス・フンジシディカス分離株およびその使用
RU2498995C2 (ru) Пептиды с большим числом мостиковых связей, выделяемые из actinomadura namibiensis
RU2385935C2 (ru) Генный кластер, участвующий в биосинтезе сафрацина, и его применение в генной инженерии
JP7086984B2 (ja) Ｓｔｒｅｐｔｏｍｙｃｅｓ ｆｕｎｇｉｃｉｄｉｃｕｓの遺伝子組換え株におけるエンデュラシジンの産生を増強するための組成物及び方法
WO2018013967A9 (en) LANTIBIOTIC VARIANTS AND USES THEREOF
EP2327789A1 (en) Novel compound signamycin, method for production thereof, and use thereof
KR101748678B1 (ko) 글라이코펩타이드 화합물 생산증대방법
WO2023057469A1 (en) Kynurenine aminotransferase and products thereof for the treatment of inflammatory bowel diseases
ES2362456T3 (es) Macrociclos de aminotiazol, sus usos como compuestos antibacterianos y procesos para su producción.
Bell Analysis and manipulation of “actagardine” gene clusters from Actinoplanes
WO2012062906A1 (en) Peptides as bioactive compounds